4 years ago

Imophoron Raises GBP 4 Million to Develop Rapid-Response Vaccines

  • Imophoron, a Bristol, UK-based developer of a novel, next generation rapid-response vaccine platform, ADDomer(TM), has secured GBP 4m in funding

  • The round was co-led by Science Creates Ventures and Octopus Ventures, alongside Jonathan Milner

  • The company intends to use the capital to continue development of its self-assembling protein sub-units: ADDomers, the core of its platform used to create its vaccines.

      • ProblemBiotechnology

      "Developing effective, rapid-response vaccines against present and future infectious diseases, including disease outbreaks, known as 'Disease X'"

      Solution

      "Imophoron's ADDomer platform uses self-assembling protein sub-units to create vaccines, enabling the rapid insertion of large numbers of peptide and protein epitopes, ideal for next-generation vaccines"

      Covered on